# Atrial Fibrillation Management

## Diagnosis
- Irregularly irregular rhythm on ECG
- Absence of distinct P waves, fibrillatory baseline
- Classification: Paroxysmal (<7 days), Persistent (>7 days), Long-standing persistent (>12 months), Permanent

## Stroke Risk Assessment — CHA2DS2-VASc Score
- **C** Congestive heart failure (1 point)
- **H** Hypertension (1 point)
- **A2** Age ≥75 (2 points)
- **D** Diabetes mellitus (1 point)
- **S2** Stroke/TIA/thromboembolism (2 points)
- **V** Vascular disease (1 point)
- **A** Age 65-74 (1 point)
- **Sc** Sex category — female (1 point)
- Score ≥2 (men) or ≥3 (women): Anticoagulation recommended
- Score 1 (men) or 2 (women): Consider anticoagulation
- Score 0 (men) or 1 (women): No anticoagulation needed

## Bleeding Risk — HAS-BLED Score
- Hypertension, Abnormal renal/liver function, Stroke, Bleeding history, Labile INR, Elderly (>65), Drugs/alcohol
- Score ≥3: High bleeding risk — does NOT contraindicate anticoagulation but warrants closer monitoring

## Anticoagulation
- **DOACs preferred** over warfarin for non-valvular AF: Apixaban 5mg BID (preferred), Rivaroxaban 20mg daily, Dabigatran 150mg BID, Edoxaban 60mg daily
- **Warfarin**: For mechanical valve, moderate-severe mitral stenosis; target INR 2.0-3.0
- Dose adjustments: Renal function (CrCl), age, weight, drug interactions

## Rate Control
- **Target**: Resting HR <110 bpm (lenient) or <80 bpm (strict if symptomatic)
- **First-line**: Beta-blockers (metoprolol, atenolol) or non-dihydropyridine CCBs (diltiazem, verapamil)
- **Second-line**: Digoxin (adjunct, not monotherapy), amiodarone (if HFrEF)
- Avoid CCBs in HFrEF

## Rhythm Control
- Consider if symptomatic despite rate control, younger patients, first episode
- **Cardioversion**: Electrical or pharmacologic; requires ≥3 weeks anticoagulation before OR TEE to exclude LAA thrombus
- **Antiarrhythmics**: Flecainide/propafenone (no structural heart disease), amiodarone/dofetilide/sotalol (structural heart disease)
- **Catheter ablation**: Pulmonary vein isolation — for drug-refractory symptomatic AF, increasingly first-line for paroxysmal AF
- Continue anticoagulation ≥4 weeks post-cardioversion regardless of method
